Robbins LLP, a prominent law firm known for championing shareholder and consumer rights, has initiated a class action lawsuit targeting Sarepta Therapeutics, Inc. This legal action represents investors who acquired shares between June 22, 2023, and June 24, 2025, and hinges on alleged misinformation regarding the safety of ELEVIDYS, Sarepta’s pioneering gene therapy for Duchenne muscular dystrophy.

The core of the lawsuit alleges that Sarepta Therapeutics misrepresented the safety profile of ELEVIDYS, failing to adequately disclose life-threatening side effects observed during clinical trials. Additionally, the complaint criticizes the company for insufficient monitoring protocols which did not effectively detect early warning signs, potentially endangering patient safety.

The urgency of the situation escalated with the announcement on March 18, 2025, that a patient had died following treatment with ELEVIDYS, which caused Sarepta’s stock to plummet more than 27%, closing at $73.54. This was closely followed by another tragic incident on June 15, where a patient succumbed to acute liver failure, leading the company to halt shipments and dosing in certain trials, and resulting in a further 42% drop in stock value to $20.91. The situation worsened when the FDA announced an investigation into the liver failure risks associated with the therapy, with stock prices dipping to $17.46.

Investors who have suffered financial losses during this tumultuous period have until August 25, 2025, to apply as a lead plaintiff in the lawsuit. Participation as a lead plaintiff is not mandatory for potential recovery from any settlements.

For those impacted, Robbins LLP offers several avenues for legal consultation and joining the class action:

- Telephone: Investors can reach out directly by calling (800) 350-6003. - Email: Direct communication can be made with attorney Aaron Dumas, Jr. via email. - Online Submission: Interested parties can also submit a form available at RobbinsLLP.com.

Robbins LLP undertakes all cases on a contingency fee basis, ensuring that clients are not liable for legal fees unless a recovery is achieved.

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a biotechnology firm focused on developing genetic medicines for rare neuromuscular diseases. The company is renowned for its contributions to treatments for Duchenne muscular dystrophy (DMD) using RNA technology, gene therapy, and gene editing.

As this legal battle unfolds, Robbins LLP continues to stand as a steadfast advocate for investor rights, committed to ensuring corporate accountability and safeguarding investor interests.